Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced continued progress on its proprietary AI platform and robotics integration as it approaches initial commercial deployment. The company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing.
This advancement marks a significant step for Oncotelic, which is focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The integration of AI and robotics into drug development processes has the potential to accelerate research, enhance biomarker discovery, and streamline regulatory processes. By leveraging its PDAOAI platform, Oncotelic aims to transform how pharmaceutical data is analyzed and applied, potentially reducing development timelines and costs.
For the pharmaceutical industry, the deployment of AI and robotics in drug development could lead to more efficient identification of therapeutic candidates, improved manufacturing consistency, and better compliance with regulatory standards. Oncotelic's platform, which incorporates a vast repository of scientific literature, allows for advanced data analysis and knowledge integration, supporting research and decision-making across the drug development lifecycle.
Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic's position in oncology and rare disease therapeutics.
The announcement underscores Oncotelic's commitment to leveraging cutting-edge technology to address critical needs in healthcare. As the company moves toward commercial deployment, stakeholders will be watching to see how this platform impacts the efficiency of pharmaceutical development and its potential to bring new therapies to market faster.
For more information, visit the company's newsroom at https://ibn.fm/OTLC and view the full press release at https://ibn.fm/2uitp.
